[HTML][HTML] 尼洛替尼和达沙替尼作为二三线药物治疗慢性髓性白血病慢性期和加速期患者的疗效及影响因素分析
袁婷， 赖悦云， 秦亚溱， 石红霞， 黄晓军… - Chinese Journal of …, 2020 - ncbi.nlm.nih.gov
… or dasatinib as second- or third-line treatment in patients with … With a median follow-up
of 21 (range, 1–135) months, the … The 2-year PFS and OS rates were 66.8% and 93.8%, …
of 21 (range, 1–135) months, the … The 2-year PFS and OS rates were 66.8% and 93.8%, …
[HTML][HTML] 氟马替尼与伊马替尼治疗初发慢性髓性白血病慢性期患者的有效性及严重血液学不良反应发生率比较
张小帅， 刘兵城， 杜新， 张龑莉， 许娜… - Chinese Journal of …, 2023 - ncbi.nlm.nih.gov
… chronic myeloid leukemia (CML). … In the imatinib cohort, the median follow-up time was 54
[interquartile range (… of 18 (IQR, 13–25) months in the flumatinib cohort, the 2-year cumulative …
[interquartile range (… of 18 (IQR, 13–25) months in the flumatinib cohort, the 2-year cumulative …
[HTML][HTML] 国产达沙替尼二线治疗慢性髓性白血病慢性期患者的疗效和安全性分析
陈怡琳， 王龙， 袁国林， 杨壮志， 黄知平… - Chinese Journal of …, 2019 - ncbi.nlm.nih.gov
… and safety of domestic dasatinib as second-line treatment for chronic myeloid … with dasatinib
were 77.5% (54/71), 72.6% (61/75) and 60.7% (51/69), respectively. By the end of follow-up, …
were 77.5% (54/71), 72.6% (61/75) and 60.7% (51/69), respectively. By the end of follow-up, …
[HTML][HTML] 尼洛替尼暴露对女性慢性髓性白血病患者妊娠结局的影响
赵慧芳， 宋永平， 李珍， 周健， 喻凤宽… - Chinese Journal of …, 2019 - ncbi.nlm.nih.gov
… To observe the pregnancy outcome among patients with chronic myeloid leukemia（CML）…
替尼（dasatinib，DAS）一线治疗慢性髓性白血病慢性期（CML-CP）患者可较伊马替尼（imatinib，IM…
替尼（dasatinib，DAS）一线治疗慢性髓性白血病慢性期（CML-CP）患者可较伊马替尼（imatinib，IM…
[HTML][HTML] BCR-ABL 激酶区突变在酪氨酸激酶抑制剂耐药慢性髓性白血病患者中的分布及其影响因素
大雨石， 亚溱秦， 悦云赖， 红霞石… - Chinese Journal of …, 2020 - ncbi.nlm.nih.gov
… in TKI-resistant patients with chronic myeloid leukemia … %) imatinib-, 152 (63.9%) nilotinib-,
and 160 (57.3%) dasatinib-… frequent mutation detected in imatinib-, nilotinib-, and dasatinib-…
and 160 (57.3%) dasatinib-… frequent mutation detected in imatinib-, nilotinib-, and dasatinib-…
[HTML][HTML] 慢性髓性白血病患者服用酪氨酸激酶抑制剂期间发生的严重血液学不良反应及其对治疗反应的影响
于露， 秦亚溱， 赖悦云， 石红霞， 黄晓军… - Chinese Journal of …, 2019 - ncbi.nlm.nih.gov
… response in newly diagnosed patients with chronic myeloid leukemia receiving tyrosine
kinase-… Data of newly diagnosed patients with CML in the chronic phase (CP) and/or accelerated …
kinase-… Data of newly diagnosed patients with CML in the chronic phase (CP) and/or accelerated …
[PDF][PDF] 获得DMR 的慢性粒细胞白血病患者停用二代TKI 的系统回顾和meta 分析
狄琼楠， 秦玲， 邓会阳， 赵颖欣 - 国际临床医学, 2020 - cn.acad-pub.com
… Dasatinib: a guide to its use in chronic myeloid leukemia in the … Successful treatment free
remission in CML after 2 year … patients with chronic myeloid leukemia in chronic phase: results …
remission in CML after 2 year … patients with chronic myeloid leukemia in chronic phase: results …
[HTML][HTML] 中国慢性髓性白血病慢性期患者报告的酪氨酸激酶抑制相关不良反应及其对日常生活的影响研究
于露， 汪海波， 江倩 - Chinese Journal of Hematology, 2016 - ncbi.nlm.nih.gov
… impact of patient reported outcome of tyrosine kinase inhibitor (TKI) related side effects
on daily life in Chinese patients with chronic myeloid leukemia (CML) in the chronic phase (CP). …
on daily life in Chinese patients with chronic myeloid leukemia (CML) in the chronic phase (CP). …
[HTML][HTML] 接受造血干细胞移植的Ph+ 急性淋巴细胞白血病患者一线应用国产达沙替尼与伊马替尼的疗效比较
杨飞， 蔡文治， 黄晓雯， 薛胜利， 傅琤琤… - Chinese Journal of …, 2018 - ncbi.nlm.nih.gov
… dasatinib, and the other 32 ones imatinib. Complete remission (CR) rates at the fourth week
of induction therapy in generic dasatinib and imatinib … generic dasatinib and imatinib groups …
of induction therapy in generic dasatinib and imatinib … generic dasatinib and imatinib groups …
氟马替尼联合多药化疗治疗费城染色体阳性急性淋巴细胞白血病的疗效和安全性分析
谭根梅， 齐凌， 纪德香， 李菲 - 中国肿瘤临床, 2022 - cjco.cn
… The patients were followed-up with a median follow-up time of 180 days (range, 75.6-458.1
days). The overall survival (OS) and recurrence-free survival (RFS) rates were 82.61% and …
days). The overall survival (OS) and recurrence-free survival (RFS) rates were 82.61% and …